Home › Immunoblastic Lymphadenopathy › Illinois › Chicago
Immunoblastic Lymphadenopathy clinical trials in Chicago, IL
4 studies for Immunoblastic Lymphadenopathy are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
RecruitingPhase 2
- Northwestern University, Chicago
- University of Illinois, Chicago
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RecruitingPhase 3
- North Western University Robert H. Lurie Comprehensive Cancer Center RHLCCC, Chicago
A Registry for People With T-cell Lymphoma
RecruitingObservational study
- Northwestern Medicine (Data Collection), Chicago
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
RecruitingPhase 1
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago
Immunoblastic Lymphadenopathy trials in other cities
- New York City, NY5 studies
- Houston, TX4 studies
- Durham, NC4 studies
- Miami, FL4 studies
- Baldwin Park, CA3 studies
- Ann Arbor, MI3 studies
- St. Louis, MO3 studies
- Boston, MA3 studies
- New Haven, CT3 studies
- Columbus, OH3 studies
- Atlanta, GA3 studies
- Rochester, MN3 studies
Other studies in Chicago
- Non-Small Cell Lung Cancer61 studies
- Breast Cancer58 studies
- Cancer (all types)51 studies
- Metastatic Cancer45 studies
- Prostate Cancer45 studies
- Obesity41 studies
- Lung Cancer41 studies
- Ovarian Cancer36 studies
- Stroke34 studies
- Colorectal Cancer33 studies
- Heart Failure31 studies
- Overweight28 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.